Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%

G Lopes, Y Wu, I Kudaba, D Kowalski, B Cho, H Turna, G De Castro, V Srimuninnimit, K Laktionov, I Bondarenko, K Kubota, G Lubiniecki, J Zhang, D Kush, T Mok

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S152
Number of pages1
JournalJournal of Thoracic Oncology
Issue number9, Suppl.
Publication statusPublished - Sept 2018
Externally publishedYes
EventIASLC Latin American Conference on Lung Cancer - Cordoba, Argentina
Duration: 15 Aug 201818 Aug 2018


  • KEYNOTE-042
  • Chemotherapy
  • Pembrolizumab
  • Programmed death ligand 1 (PD-L1)

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this